NY-ROBOSENSE
13.2.2020 15:02:10 CET | Business Wire | Press release
RoboSense’s automotive MEMS LiDAR“RS-LiDAR-M1” has been named a finalist in transportation &Logistics category for the 2020 Edison Awards. The Edison Awards, named after Thomas Alva Edison, recognizes and honors the world’s best innovations and innovators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005321/en/
The Edison Awards is one of the world's prestigious awards that symbolize the persistence and excellence in innovation and honors the most innovative products and business leaders in the world. It is Established in 1987 and named after inventor Thomas Alva Edison and sometimes referred to as “The Oscars of Innovation”. All the winners were chosen as the "best of the best" by the globe review panel consist of 3,000 senior business executives and academics.
The RoboSense RS-LiDAR-M1 is the world’s first and smallest MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 meets every automotive-grade requirement, including intelligence, low cost, stability, simplified structure and small size, vehicle body design friendliness, and algorithm processed semantic-level perception output results.
As the game-changing product in the autonomous driving field, the RS-LiDAR-M1 hard-ware only version is currently available for customers, with a retail price of $1898. The smart sensor version is currently available for key customers who have purchased the solid-state LiDAR A-C Sample Kit. At CES 2020, the RoboSense RS-LiDAR-M1 also demonstrated that it is the world’s first and only Smart LiDAR capable of real road tests on open roads.
RoboSense Smart LiDAR Sensor RS-LiDAR-M1 installed on a vehicle
“Winning of the 2020 Edison Award is a recognition of RoboSense’s innovation technology towards the future mobility and its benefits for the human driving safety”, Dr. Leilei Shinohara, RoboSense Co-partner and Vice President said, “with the achievement of the IATF 16949 Certification, RoboSense is qualified to supply to automotive customers. We are confident that the RS-LiDAR-M1 is the best choice for the mass production of autonomous driving. We continuously focus on the validation and verification of performance and quality of RS-LiDAR-M1 as an automotive-grade product”.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
Attracted an all-star team from leading corporations and institutions around the world，there are 500+ employees in 6 global locations-Shenzhen, Beijing, Shanghai, Suzhou, Stuttgart, and Silicon Valley to support RoboSense's fast-growing in innovation and development. Until 2019, RoboSense owns more than 500 patents globally. For more information, see the website:
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005321/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom